DataMeds AI, Inc. has entered into a stock purchase agreement to acquire Helomics Corporation from Axe Compute Inc. The transaction, executed on September 11, 2026, closed simultaneously with the signing of the agreement. Under the terms of the deal, DataMeds acquired all issued and outstanding shares of Helomics, making the company a wholly owned subsidiary.
The purchase consideration consists of two components. DataMeds issued 636,328 shares of its common stock to Axe Compute, representing approximately 19.99% of the shares outstanding prior to the transaction. Additionally, the company issued a convertible promissory note with an original principal amount of $1,363,672. The note accrues interest at a simple rate of 7% per annum and matures on September 11, 2029, unless converted earlier.
The convertible note allows the holder to convert the principal and accrued interest into DataMeds common stock at a price of $1.00 per share. This conversion is subject to stockholder approval and will occur automatically upon the receipt of that approval. The note contains anti-dilution provisions and is a general unsecured obligation of DataMeds, subordinated to existing indebtedness.
DataMeds agreed to call a stockholder meeting within 75 days of the closing to seek approval for the issuance of shares related to the note. Axe Compute has agreed to vote its shares in favor of the board’s recommendations for a period of six months following the closing. Furthermore, Axe Compute is restricted from transferring the consideration shares or the note for 12 months following the transaction.
According to a press release issued on September 15, 2026, the acquisition includes Helomics’ CLIA/CAP-certified clinical laboratory, its Predictive Oncology contract research organization central lab services business, and associated equipment. The press release notes that the acquisition provides operational capital to support DataMeds' campaign to improve patient outcomes and expands its services into cancer diagnosis and treatment.
